Literature DB >> 28566935

Variations in Echogenicity in Carotid and Femoral Atherosclerotic Plaques with Pycnogenol + Centella Asiatica Supplementation.

Gianni Belcaro1, Umberto Cornelli1.   

Abstract

This registry study evaluated echogenicity of carotid-femoral plaques in asymptomatic subjects with increased oxidative stress and risk factors (mild hypertension, hypercholesterolemia). Supplementation with the combination Pycnogenol-CA (centella asiatica) on the echogenicity of plaques was assessed at 6 months (79 subjects). A standard management (SM) plan was used in all subjects (control of risk factors, lifestyle changes); 36 subjects used the supplements +SM; 43 SM only. The groups were comparable. High-resolution ultrasound evaluated echogenicity and plaque structure. Pycnogenol (150 mg/day) and CA (Centellicum, 450 mg/day) were used. At 6 months, cholesterol was reduced (p < 0.05) in both groups (difference between groups not significant). At 6 months, plasma free radicals were decreased with the supplements (17.64%; p < 0.05; vs <2% in controls). The plaque stability index increased from 11.22;2.3 to 22.4;1.1 (p < 0.05) with the supplements; no significant changes were seen in controls. Plaque echogenicity (% of "whiter" component in images) increased with supplementation from 16.7;1.7% to 34.2;2% (p < 0.05); no variations were observed in controls. The maximum plaque height decreased (p < 0.05) with the supplements. No significant variations were observed in controls. Plaque length was decreased (p < 0.05) in the supplement group with no changes in controls. The number of plaques (carotid, femoral bifurcations) decreased with supplementation; no significant changes were observed in controls. No adverse events, tolerability problems, or variations in routine blood tests were recorded. The combination Pycnogenol-CA appears to improve echogenicity and stability of complex plaques in 6 months.

Entities:  

Keywords:  Centella asiatica; Pycnogenol; atherosclerosis; cardiovascular events; echogenicity; oxidative stress; plaques

Year:  2016        PMID: 28566935      PMCID: PMC5446256          DOI: 10.1055/s-0036-1594292

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  37 in total

1.  Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE study(1)).

Authors:  G Belcaro; A N Nicolaides; G Ramaswami; M R Cesarone; M De Sanctis; L Incandela; P Ferrari; G Geroulakos; A Barsotti; M Griffin; S Dhanjil; M Sabetai; M Bucci; G Martines
Journal:  Atherosclerosis       Date:  2001-06       Impact factor: 5.162

2.  Evidence-based management of carotid artery disease.

Authors:  Sibu P Saha; Thomas F Whayne; Debabrata Mukherjee
Journal:  Int J Angiol       Date:  2010

3.  Ultrasonic image analysis of the arterial wall in atherosclerosis.

Authors:  L D Coen; G Ramaswami; P C Ma; G Belcaro; N Nicolaides
Journal:  Panminerva Med       Date:  1998-03       Impact factor: 5.197

Review 4.  TECA (Titrated Extract of Centella Asiatica): new microcirculatory, biomolecular, and vascular application in preventive and clinical medicine. A status paper.

Authors:  G Belcaro; F-X Maquart; M Scoccianti; M Dugall; M Hosoi; M R Cesarone; R Luzzi; U Cornelli; A Ledda; B Feragalli
Journal:  Panminerva Med       Date:  2011-09       Impact factor: 5.197

Review 5.  Pleiotropic effects of statins.

Authors:  J A Farmer
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

6.  Pleiotropic effects of statins in atherosclerosis and diabetes.

Authors:  S Bellosta; N Ferri; L Arnaboldi; F Bernini; R Paoletti; A Corsini
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

7.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

8.  Pycnogenol® and Centella asiatica to prevent asymptomatic atherosclerosis progression in clinical events.

Authors:  Gianni Belcaro; Mark Dugall; Edmondo Ippolito; Morio Hosoi; Umberto Cornelli; Andrea Ledda; Marco Scoccianti; Maria R Cesarone; Luciano Pellegrini; Roberta Luzzi; Marcello Corsi; Beatrice Feragalli
Journal:  Minerva Cardioangiol       Date:  2015-10-27       Impact factor: 1.347

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Withdrawal of cerivastatin from the world market.

Authors:  Curt D Furberg; Bertram Pitt
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.